Author/Authors :
Dao، نويسنده , , Pascal and Jarray، نويسنده , , Rafika and Smith، نويسنده , , Nikaia and Lepelletier، نويسنده , , Yves and Coq، نويسنده , , Johanne Le and Lietha، نويسنده , , Daniel and Hadj-Slimane، نويسنده , , Réda and Herbeuval، نويسنده , , Jean-Philippe and Garbay، نويسنده , , Christiane and Raynaud، نويسنده , , Françoise and Chen، نويسنده , , Huixiong، نويسنده ,
Abstract :
FAK and FGFR2 signaling pathways play important roles in cancer development, progression and tumor angiogenesis. PHM16 is a novel ATP competitive inhibitor of FAK and FGFR2. To evaluate the therapeutic efficacy of this agent, we examined its anti-angiogenic effect in HUVEC and its anti-tumor effect in different cancer cell lines. We showed PHM16 inhibited endothelial cell viability, adherence and tube formation along with the added ability to induce endothelial cell apoptosis. This compound significantly delayed tumor cell growth. Together, these data showed that inhibition of both FAK and FGFR2 signaling pathways can enhance anti-tumor and anti-angiogenic activities.
Keywords :
FAK , Inhibitor , Angiogenesis , Fgfr2 , cancer
